Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Employees

483

Sector

Biotechnology & Medical Research

More about the company

Delayed Nasdaq 08:00:00 20/11/24 am AEDT			5-day change	1st Jan Change
4.840 ^USD	+3.20%		-.--%	-

21/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index	CI
21/11/24	Recursion Pharmaceuticals, Exscientia Complete Business Combination	MT

Market Cap	500M 661M 590M 550M 941M 63.97B 950M 6.61B 2.58B 32.51B 2.48B 2.43B 105B	P/E 2022	-4.55x	P/E 2023	-4.28x
Enterprise Value	156M 206M 184M 171M 293M 19.93B 296M 2.06B 805M 10.13B 773M 756M 32.57B	EV / Sales 2022	1.9x	EV / Sales 2023	14.2x
Free-Float	36.87%	Yield 2022 *	-	Yield 2023	-

21/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from S&P Global BMI Index	CI
21/11/24	Recursion Pharmaceuticals, Exscientia Complete Business Combination	MT
20/11/24	Recursion Appoints Ben Taylor as Chief Financial Officer	CI
20/11/24	Recursion Announces Management Changes	CI
20/11/24	Recursion Pharmaceuticals, Inc. completed the acquisition of Exscientia plc.	CI
20/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Composite Index	CI
20/11/24	Exscientia plc(NasdaqGS:EXAI) dropped from NASDAQ Biotechnology Index	CI
14/11/24	Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination	MT
08/11/24	Exscientia plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
16/10/24	Exscientia Expects $15 Million in Milestone Payments From Sanofi	MT
04/09/24	Exscientia plc Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 07:00 AM
15/08/24	Exscientia plc Reports Impairment for the Second Quarter Ended June 30, 2024	CI
15/08/24	Exscientia plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

09/08/24	TD Cowen Downgrades Exscientia to Hold	MT
09/07/24	TD Cowen Initiates Exscientia at Buy	MT
18/10/23	Barclays Cuts Price Target on Exscientia to $10 From $12, Maintains Overweight Rating	MT
11/10/23	Morgan Stanley Cuts Exscientia Price Target to $7 From $14, Maintains Equal Weight Rating	MT
09/10/23	Berenberg Bank Adjusts Exscientia to $10 From $14, Maintains Buy Rating	MT

Exscientia plc Stock

Stocks

EXAI

US30223G1022

Biotechnology & Medical Research

Valuation: Exscientia plc

Latest news: Exscientia plc

Analysts' recommendations: Exscientia plc

Press Releases: Exscientia plc

News in other languages: Exscientia plc

Quotes and Performance

Price Extremes

Managers and Directors: Exscientia plc

Other Biotechnology & Medical Research

Financials

Company Profile

21/11/24	Exscientia : Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery Form 6 K	PU
20/11/24	Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery	AQ
14/11/24	Exscientia : Recursion and Exscientia Shareholders Approve the Proposed Combination Form 6 K	PU
08/11/24	Exscientia : Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive (Loss)/Income for the three and nine months ended September 30, 2024 and 2023 Form 6 K	PU
06/11/24	Exscientia : FIRST AMENDMENT TO TRANSACTION AGREEMENT Form 6 K	PU

17/10/24	Exscientia franchit des étapes importantes pour deux de ses programmes dans le cadre de sa collaboration avec Sanofi
17/10/24	Exscientia erreicht Meilensteine für zwei Programme im Rahmen der Zusammenarbeit mit Sanofi
10/10/24	Exscientia présentera de nouvelles données précliniques pour les inhibiteurs de la LSD1 et du MALT1 conçus par l'IA à l'ENA 2024
10/10/24	Exscientia präsentiert auf der ENA 2024 neue präklinische Daten für KI-gestützte LSD1- und MALT1-Inhibitoren
29/08/24	Exscientia wird auf der 22nd Annual Global Healthcare Conference Präsentation durchführen

Manager	Title	Age	Since
Marie-Louise Fjaellskog CTO	Chief Tech/Sci/R&D Officer	61	06/06/2024
Eileen Jennings-Brown CTO	Chief Tech/Sci/R&D Officer	-	01/05/2022
John Overington CTO	Chief Tech/Sci/R&D Officer	-	01/05/2024

Director	Title	Age	Since
Mario Polywka BRD	Director/Board Member	63	28/09/2017
Robert Ghenchev BRD	Director/Board Member	43	01/05/2020
Elizabeth Crain CHM	Chairman	61	12/02/2024

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXSCIENTIA PLC	+3.20%	-.--%	-.--%	+4.09%	633M
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	74.68B
ARGENX SE	-15.86%	-16.67%	+3.92%	+50.90%	58.7B
LONZA GROUP AG	-2.39%	-2.05%	+4.29%	+31.33%	48.36B
REVOLUTION MEDICINES, INC.	-6.35%	-8.63%	+293.39%	+638.59%	43.05B
IQVIA HOLDINGS INC.	+0.30%	-0.71%	+29.05%	+29.74%	42.48B
BEONE MEDICINES AG	-3.82%	-2.41%	-0.27%	+102.63%	41.39B
CELLTRION, INC.	-2.13%	+1.07%	+7.51%	+50.31%	31.29B
BIONTECH SE	-3.35%	-4.95%	-13.38%	-15.78%	23.93B
INSMED INCORPORATED	-1.24%	-7.47%	-37.90%	+309.96%	22.22B
Average	-3.47%	-2.37%	+33.12%	+128.97%	38.67B
Weighted average by Cap.	-4.83%	-1.88%	+43.17%	+134.88%

	2022	2023
Net sales	27.22M 35.97M 32.12M 29.97M 51.23M 3.48B 51.73M 360M 141M 1.77B 135M 132M 5.69B	20.08M 26.53M 23.69M 22.1M 37.78M 2.57B 38.15M 265M 104M 1.31B 99.62M 97.46M 4.2B
Net income	-119M -157M -140M -131M -223M -15.2B -226M -1.57B -614M -7.72B -589M -576M -24.83B	-146M -193M -172M -161M -275M -18.68B -277M -1.93B -755M -9.49B -724M -708M -30.53B
Net Debt	-492M -650M -580M -542M -926M -62.96B -935M -6.5B -2.54B -31.99B -2.44B -2.39B -103B	-344M -455M -406M -379M -648M -44.04B -654M -4.55B -1.78B -22.38B -1.71B -1.67B -71.97B

3 years	3.8	7.91
5 years	3.8	25.16
10 years	3.8	30.38